Veeva Systems’ Oct. 22 analysis found that biopharma quality-control labs lag research and development and manufacturing in operational maturity. It identified paper records and disconnected data as major efficiency drains that delay batch approvals and product releases.
Veeva Systems’ analysis found that biopharma quality-control labs lag research and development and manufacturing in operational maturity. Paper records and disconnected data were identified as major efficiency drains, delaying batch approvals and product releases.
The analysis cited budget constraints, cultural resistance and complex legacy systems as obstacles. Custom integrations require substantial investment and costly maintenance, while weak connections with quality management can slow deviation resolution and disconnected on-premises systems make multisite changes expensive and risky.
The analysis said faster-moving companies are positioning labs as strategic functions to secure funding and prioritizing cloud-based systems within unified quality strategies.
